BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 18301365)

  • 1. RotaTeq vaccine adverse events and policy considerations.
    Geier DA; King PG; Sykes LK; Geier MR
    Med Sci Monit; 2008 Mar; 14(3):PH9-16. PubMed ID: 18301365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postmarketing monitoring of intussusception after RotaTeq vaccination--United States, February 1, 2006-February 15, 2007.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(10):218-22. PubMed ID: 17363890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rotavirus live, oral, pentavalent vaccine.
    Tom-Revzon C
    Clin Ther; 2007 Dec; 29(12):2724-37. PubMed ID: 18201590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pentavalent rotavirus vaccine, RotaTeq.
    Matson DO
    Semin Pediatr Infect Dis; 2006 Oct; 17(4):195-9. PubMed ID: 17055370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rotavirus vaccination coverage and adherence to the Advisory Committee on Immunization Practices (ACIP)-recommended vaccination schedule--United States, February 2006-May 2007.
    ;
    MMWR Morb Mortal Wkly Rep; 2008 Apr; 57(15):398-401. PubMed ID: 18418345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007.
    Haber P; Patel M; Izurieta HS; Baggs J; Gargiullo P; Weintraub E; Cortese M; Braun MM; Belongia EA; Miller E; Ball R; Iskander J; Parashar UD
    Pediatrics; 2008 Jun; 121(6):1206-12. PubMed ID: 18519491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of rotavirus disease: guidelines for use of rotavirus vaccine.
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2007 Jan; 119(1):171-82. PubMed ID: 17200286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe.
    Vesikari T; Itzler R; Karvonen A; Korhonen T; Van Damme P; Behre U; Bona G; Gothefors L; Heaton PM; Dallas M; Goveia MG
    Vaccine; 2009 Dec; 28(2):345-51. PubMed ID: 19879226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine.
    Belongia EA; Irving SA; Shui IM; Kulldorff M; Lewis E; Yin R; Lieu TA; Weintraub E; Yih WK; Li R; Baggs J;
    Pediatr Infect Dis J; 2010 Jan; 29(1):1-5. PubMed ID: 19907356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.
    Ciarlet M; Schödel F
    Vaccine; 2009 Dec; 27 Suppl 6():G72-81. PubMed ID: 20006144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on pentavalent rotavirus vaccine (RotaTeq) in the prevention of rotavirus gastroenteritis in Europe.
    Plosker GL
    BioDrugs; 2010 Dec; 24(6):411-4. PubMed ID: 21043548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rotavirus vaccines: new drug. Rotavirus infection: one case of severe diarrhoea prevented per 100 vaccinated infants.
    Prescrire Int; 2007 Feb; 16(87):3-6. PubMed ID: 17323513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
    Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF
    Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007.
    Hua W; Izurieta HS; Slade B; Belay ED; Haber P; Tiernan R; Woo EJ; Iskander J; Braun MM; Ball R
    Pediatr Infect Dis J; 2009 Nov; 28(11):943-7. PubMed ID: 19755926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of an ideal rotavirus vaccine.
    Reisinger KS; Block SL
    Clin Pediatr (Phila); 2008 Jul; 47(6):555-63. PubMed ID: 18467670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS).
    Bakare N; Menschik D; Tiernan R; Hua W; Martin D
    Vaccine; 2010 Sep; 28(40):6609-12. PubMed ID: 20674876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RotaTeq: a three-dose oral pentavalent reassortant rotavirus vaccine.
    Chandran A; Santosham M
    Expert Rev Vaccines; 2008 Dec; 7(10):1475-80. PubMed ID: 19053204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rotavirus vaccines.
    Vesikari T
    Scand J Infect Dis; 2008; 40(9):691-5. PubMed ID: 19086243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intussusception among recipients of rotavirus vaccine--United States, 1998-1999.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1999 Jul; 48(27):577-81. PubMed ID: 10428095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.
    Plosker GL
    Drugs; 2010 Jun; 70(9):1165-88. PubMed ID: 20518582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.